Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Wanda Lopez"'
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Sa A. Wang, Zeev Estrov, Susan O'Brien, Keyur P. Patel, Tapan M. Kadia, Gautam Borthakur, William G. Wierda, Philip A. Thompson, Nitin Jain, Naveen Garg, Prithviraj Bose, Alessandra Ferrajoli, Varsha Gandhi, Koji Sasaki, Jeffrey L. Jorgensen, Naveen Pemmaraju, Ana Ayala, Xuemei Wang, Hagop M. Kantarjian, Wanda Lopez, Koichi Takahashi, William Plunkett, Michael J. Keating, Jan A. Burger, Rashmi Kanagal-Shamanna
Publikováno v:
Blood. 134:357-357
BACKGROUND Combined fludarabine, cyclophosphamide, and rituximab (FCR) was the preferred regimen for young fit patients (pts) with CLL. The CLL10 trial established FCR as the preferred first-line chemoimmunotherapy (CIT). Recently, the E1912 trial co
Autor:
Varsha Gandhi, Susan O'Brien, Hagop M. Kantarjian, Wanda Lopez, Prithviraj Bose, William G. Wierda, Zeev Estrov, Philip A. Thompson, Xuemei Wang, William Plunkett, Nitin Jain, Jan A. Burger, Naveen Garg, Michael J. Keating, Keyur P. Patel, Rashmi Kanagal-Shamanna, Koichi Takahashi, Gautam Borthakur, Alessandra Ferrajoli
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S13-S14
Autor:
Carlos E. Bueso-Ramos, Joseph D. Khoury, Jan A. Burger, Padmanee Sharma, Jorge Blando, James P. Allison, Beenu Thakral, William G. Wierda, Sreyashi Basu, Hagop M. Kantarjian, Wanda Lopez, Nitin Jain, Tapan M. Kadia, Naveen Pemmaraju, Zeev Estrov, Michael J. Keating, Susan O'Brien, Alessandra Ferrajoli, Philip A. Thompson
Publikováno v:
Blood. 132:296-296
Background: Outcomes of patients (pts) with Richter transformation (RT) remain dismal with a median survival of less than 1 year with chemoimmunotherapy (CIT). Dysfunction of T cells, NK cells and other immune subsets is common in pts with CLL. Check
Autor:
Alessandra Ferrajoli, Varsha Gandhi, William G. Wierda, Michael J. Keating, Nitin Jain, Jan A. Burger, Gautam Borthakur, Philip A. Thompson, Prithviraj Bose, Zeev Estrov, Hagop M. Kantarjian, William Plunkett, Susan O'Brien, Wanda Lopez
Publikováno v:
Journal of Clinical Oncology. 35:7522-7522
7522 Background: Pts with mutated IGHV ( IGHV-M) have favorable long-term outcomes after FCR. Methods: We designed an investigator-initiated phase II trial with ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for previously untreate
Autor:
Zeev Estrov, James P. Allison, Philip A. Thompson, Naveen Pemmaraju, Hagop M. Kantarjian, Sattva S. Neelapu, Wanda Lopez, Michael J. Keating, Jorge E. Cortes, Jan A. Burger, Carlos E. Bueso-Ramos, Padmanee Sharma, Beenu Thakral, Alessandra Ferrajoli, Susan O'Brien, Maro Ohanian, Jorge Blando, Sreyashi Basu, William G. Wierda, Nitin Jain
Publikováno v:
Blood. 128:59-59
Background: Treatment outcomes for patients with CLL have improved with the use of targeted agents, such as ibrutinib, yet complete remissions (CR) are rare, and the outcomes of patients with relapsed CLL still remain suboptimal. T cells from patient